Posted by Michael Wonder on 08 Nov 2024
Newly funded medicine to benefit 110 more people with thyroid, liver, and kidney cancer
8 November 2024 - PHARMAC has decided to fund lenvatinib from 1 December 2024 for people with some types of thyroid, liver, and kidney cancer.
Lenvatinib (Lenvima) stops the number of cancer cells from increasing, slowing the cancer’s progression. The medicine is taken as oral capsule that people can take at home.
